CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

被引:5
|
作者
Yi, Yonglin [1 ]
Qiu, Zhengang [2 ]
Yao, Zifu [1 ,3 ]
Lin, Anqi [1 ]
Qin, Yimin [1 ]
Sha, Ruizhan [1 ]
Wei, Ting [1 ]
Wang, Yanru [1 ]
Cheng, Quan [4 ]
Zhang, Jian [1 ]
Luo, Peng [1 ]
Shen, Weitao [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China
[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Guangzhou, Peoples R China
[3] Southern Med Univ, Clin Med Sch 1, Guangzhou, Peoples R China
[4] Ctr South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China
基金
中国国家自然科学基金;
关键词
small cell lung cancer; CAMSAP1; platinum-based chemotherapy; drug sensitivity; biomarker; ACTIVATED PROTEIN-KINASE; TGF-BETA; B-CELLS; EXPRESSION; CHEMORESISTANCE; IMMUNOTHERAPY; SURVIVAL; FAMILY; MECHANISMS; MANAGEMENT;
D O I
10.3389/fcell.2021.770811
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platinum-based chemotherapy is the first-line treatment for small cell lung cancer (SCLC). However, due to patients developing a resistance to the drug, most experience relapse and their cancer can become untreatable. A large number of recent studies have found that platinum drug sensitivity of various cancers is affected by specific gene mutations, and so with this study, we attempted to find an effective genetic biomarker in SCLC patients that indicates their sensitivity to platinum-based drugs. To do this, we first analyzed whole exome sequencing (WES) and clinical data from two cohorts to find gene mutations related to the prognosis and to the platinum drug sensitivity of SCLC patients. The cohorts used were the Zhujiang cohort (N = 138) and the cohort reported by George et al. (N = 101). We then carried out gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) to investigate possible molecular mechanisms through which these gene mutations affect patient prognosis and platinum drug sensitivity. We found that for SCLC patients, CAMSAP1 mutation can activate anti-tumor immunity, mediate tumor cell apoptosis, inhibit epithelial-mesenchymal transition (EMT), improve prognosis, and improve platinum drug sensitivity, suggesting that CAMSAP1 mutation may be a potential biomarker indicating platinum drug sensitivity and patient prognosis in SCLC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Effect of BRCA1 Haplotype on Survival of Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Kim, Hong-Tae
    Lee, Jong-Eun
    Shin, Eun-Soon
    Yoo, Yeon-Kyeong
    Cho, Jae-Hwa
    Yun, Min-Hye
    Kim, Yeul-Hong
    Kim, Se-Kyu
    Kim, Hyun-Jung
    Jang, Tae-Won
    Kwak, Seung-Min
    Kim, Chul-Soo
    Ryu, Jeong-Seon
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5972 - 5979
  • [22] Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy
    Butkiewicz, Dorota
    Drosik, Anna
    Suwinski, Rafal
    Krzesniak, Malgorzata
    Rusin, Marek
    Kosarewicz, Agata
    Rachtan, Jadwiga
    Matuszczyk, Iwona
    Gawkowska-Suwinska, Marzena
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (07) : E1100 - E1108
  • [23] Texture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy
    Wang, M.
    Ma, X.
    ANNALS OF ONCOLOGY, 2019, 30 : 10 - 10
  • [24] Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy
    Ioannidis, Georgios
    Souglakos, John
    Georgoulias, Vassilis
    LUNG CANCER MANAGEMENT, 2013, 2 (04) : 281 - 293
  • [25] Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
    Yamashita, Fumie
    Azuma, Koichi
    Yoshida, Tsukasa
    Yamada, Kazuhiko
    Kawahara, Akihiko
    Hattori, Satoshi
    Takeoka, Hiroaki
    Zaizen, Yoshiaki
    Kawayama, Tomotaka
    Kage, Masayoshi
    Hoshino, Tomoaki
    PLOS ONE, 2013, 8 (08):
  • [26] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Angel Molina, Miguel
    Robles, Ana I.
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2017, 771 : 32 - 58
  • [27] VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Qi, Huijie
    Zhang, Wenxin
    Wang, Yan
    Ge, Mengxi
    Wang, Tianxiao
    Zhang, Liudi
    Zhong, Mingkang
    Shi, Xiaojin
    Liang, Xiaohua
    Zhan, Qiong
    Li, Qunyi
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (01) : 53 - 62
  • [28] ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
    Kalikaki, Aristea
    Voutsina, Alexandra
    Koutsopoulos, Anastasios
    Papadaki, Chara
    Sfakianaki, Maria
    Yachnakis, Emmanouel
    Xyrafas, Alexandros
    Kotsakis, Athanasios
    Agelaki, Sofia
    Souglakos, John
    Mavroudis, Dimitrios
    Georgoulias, Vassilis
    CANCER INVESTIGATION, 2015, 33 (04) : 107 - 113
  • [29] No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy
    Yuan, Peng
    Liu, Li
    Wu, Chen
    Zhong, Rong
    Yu, Dianke
    Wu, Jing
    Xu, Yihua
    Nie, Shaofa
    Miao, Xiaoping
    Sun, Yan
    Xu, Binghe
    Lin, Dongxin
    CANCER BIOLOGY & THERAPY, 2010, 10 (09) : 858 - 863
  • [30] Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
    Sullivan, Ivana
    Salazar, Juliana
    Majem, Margarita
    Pallares, Cinta
    del Rio, Elisabeth
    Paez, David
    Baiget, Montserrat
    Barnadas, Agusti
    CANCER LETTERS, 2014, 353 (02) : 160 - 166